FinnCap began coverage on shares of Shield Therapeutics (LON:STX) in a research note issued to investors on Tuesday, ThisIsMoney.Co.Uk reports. The firm issued a corporate rating and a GBX 200 ($2.61) target price on the stock.
A number of other research analysts have also recently weighed in on STX. Peel Hunt reiterated a buy rating on shares of Shield Therapeutics in a report on Tuesday, January 22nd. Liberum Capital reiterated a buy rating on shares of Shield Therapeutics in a report on Tuesday, January 22nd.
Shares of Shield Therapeutics stock opened at GBX 105 ($1.37) on Tuesday. Shield Therapeutics has a twelve month low of GBX 24 ($0.31) and a twelve month high of GBX 100 ($1.31). The firm has a market capitalization of $122.94 million and a P/E ratio of -70.00.
In related news, insider Mark Sampson acquired 22,042 shares of the business’s stock in a transaction on Thursday, April 25th. The shares were bought at an average cost of GBX 91 ($1.19) per share, with a total value of £20,058.22 ($26,209.62). Also, insider James M. Karis acquired 4,000 shares of the business’s stock in a transaction on Tuesday, April 16th. The stock was bought at an average cost of GBX 81 ($1.06) per share, for a total transaction of £3,240 ($4,233.63).
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.
See Also: Are FAANG stocks a good investment?
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.